Академический Документы
Профессиональный Документы
Культура Документы
2016 2017
Make a Strategy
to Reach LDL-C Goal
Strategy for LOW and MODERATE risk patients
Drug Treatment
Risk Level Drug
Low Statin
Moderate Statin
Very High
Statin or Statin + Ezetimibe
(no ASCVD or DM)
Very High Statin or Statin + Ezetimibe
(ASCVD or DM with TOD or
Major RF) or Statin + PCSK9 Inhibitor
Strategy to Reach LDL-C Goal
Risk level
LDL-C target not achieved LDL-C target not achieved LDL-C target not achieved
NO NO
At LDL-C goal? Ezetimibe 10 mg At LDL-C goal?
YES (<70 mg/dL) should be considered (<70 mg/dL) YES
LDL-C Rapid
NO >140 mg/dL? progression of NO
(requiring >50% reduction ASCVD and LDL-C
to reach goal) >100 mg/dL
YES
Mean %
Change
in LDL-C
From
Untreated
Baseline
p<0.002 vs atorvastatin 10 mg; simvastatin 10, 20, 40 mg; †p<0.002 vs atorvastatin 20, 40
mg; simvastatin 20, 40, 80 mg; pravastatin 20, 40 mg; ‡ p<0.002 vs atorvastatin 40 mg;
simvastatin 40, 80 mg; pravastatin 40 mg
Jones PH et al. Am J Cardiol.. 2003;92:152–160
Efficacy of Combination of Ezetimibe and
Statins in Lowering LDL-C
12 20
Placebo Placebo
10
16
8
Participants with Event (%)
0 0
0 2 4 6 8 10 12 14 16 0 2 4 6 8 10 12 14 16
Years since Randomization Years since Randomization
No. at Risk No. at Risk
Placebo 3293 3254 3185 3113 3022 2902 2785 2114 Placebo 3293 3199 3071 2953 2841 2691 2549 1903
Pravastatin 3302 3275 3223 3158 3068 2974 2835 2177 Pravastatin 3302 3237 3157 3065 2943 2819 2675 2026
Yes No
Non-HDL-C = TC - HDL
How often should lipids be tested once a patient has reached the
target or optimal lipid level?
– Annually (if there is no adherence problems or other specific
reasons for more frequent reviews)
Catapano AL, et al. Eur Heart J. 2016;37:2999-
3058
Monitoring Liver Enzymes
How often should liver enzymes (SGPT) be routinely measured in
patients on lipid-lowering drugs?
– Before treatment
– Once 8-12 weeks after starting a drug treatment or after dose
increase
– Routine control of SGPT thereafter is not recommended during
lipid-lowering treatment
What if liver enzymes become elevated in a person taking lipid-
lowering drugs?
If SGPT<3x ULN:
– Continue therapy.
– Recheck liver enzymes in 4-6 weeks
If value rises ≥3x ULN:
– Stop lipid-lowering therapy or reduce dose and recheck liver
enzymes within 4-6 weeks.
– Cautious reintroduction of therapy may be considered after
SGPT has returned to normal.
– If SGPT remains elevated check for other reasons
Catapano AL, et al. Eur Heart J. 2016;37:2999-
3058
Consider if Statin-Attributed Muscle Symptoms
Favour Statin Continuation/Reinitiation
Symptoms improve:
Symptoms persist:
second statin at usual or
statin re-challenge 1) Low-dose third efficacious 1) Low-dose second
starting dose
(potent)+ statin efficacious+ statin
2) Efficacious+ statin with 2) Efficacious+ statin with
Symptom-free: Symptoms alternate day or once/twice alternate day or once/twice
continue statin re-occur weekly dosing regimen weekly dosing regimen
Ezetimibe